Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy

Journal of NeuroVirology

Volumn 9, Issue 3, 2003, Pages 411-419

  Royal III, Walter ^a   Dupont, B ^b   McGuire, D ^c   Chang, L ^d   Goodkin, K ^e   Ernst, T ^d   Post, M J ^e   Fish, D ^f   Pailloux, G ^g   Poncelet, H ^g   Concha, M ^e   Apuzzo, L ^h   Singer, E ⁱ  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HIV Institute   (United States)

^d Brookhaven Institute   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f ALBANY MEDICAL CENTER   (United States)

^g INSTITUT PASTEUR   (France)

^h JOHNS HOPKINS HOSPITAL   (United States)

ⁱ VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

HIV 1; MRI; Polyomavirus; Topoisomerases; Viral encephalitis

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; CAMPTOTHECIN DERIVATIVE; DIDANOSINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDINAVIR; LAMIVUDINE; STAVUDINE; TOPOTECAN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG OVERDOSE; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; HEALTH STATUS; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; NAUSEA AND VOMITING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SAMPLE SIZE; SCORING SYSTEM; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS LOAD;

HERPES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; POLYOMAVIRUS; SIMPLEXVIRUS;

EID: 0038107610     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/713831540     Document Type: Article

References (35)

1. Barnett AA (1996). FDA approve bark-derived drug. Lancet 347: 1613.
2. Berger JR (2000). Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol 2: 361-368.
3. Berger JR, Kaszovitz B, et al (1987). Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 107: 78-87.
4. Berger JR, Major EO (1999). Progressive multifocal leukoencephalopathy. Semin Neurol 19: 193-200.
5. Brambilla AM, Castagna A, et al (1999). Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. J Neurol 246: 723-725.
6. Brown P, Tsai T, et al (1975). Seroepidemiology of human papovaviruses. Discovery of virgin populations and some unusual patterns of antibody prevalence among remote peoples of the world. Am J Epidemiol 102: 331-340.
7. Chang L, Ernst T, et al (1997). Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 48: 836-845.
8. Clifford DB, Yiannoutsos C, et al (1999). HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52: 623-625.
9. De Luca A, Giancola ML, et al (2000). Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 14: F117-F121.
10. Dore GJ, Correll PK, et al (1999). Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13: 1249-1253.
11. Dworkin MS, Wan PC, et al (1999). Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 180: 621-625.
12. Enting RH, Portegies P (2000). Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy. J Neurol 247: 134-138.
13. Ernst T, Chang L, et al (1999). Progressive multifocal leukoencephalopathy and human immunodeficiency virus-associated white matter lesions in AIDS: magnetization transfer MR imaging. Radiology 210: 539-543.
14. Evans RH, Scadden DT (2000). Haematological aspects of HIV infection. Baillieres Best Pract Res Clin Haematol 13: 215-230.
15. Fong IW, Toma E (1995), The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group. Clin Infect Dis 20: 1305-1310.
16. Gasnault J, Kousignian P, et al (2001). Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 7: 375-381.
17. Gasnault J, Taoufik Y, et al (1999). Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 5: 421-429.
18. Geschwind MD, Skolasky RI, et al (2001). The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J NeuroVirol 7: 353-357.
19. Hochster H, Liebes L, et al (1994). Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12: 553-559.
20. Huang SS, Skolasky RL, et al (1998). Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol 4: 324-332.
21. Itti L, Chang L, et al (2001). Segmentation of progressive multifocal leukoencephalopathy lesions in fluid-attenuated inversion recovery magnetic resonance imaging. J Neuroimaging 11: 412-417.
22. Kerr DA, Chang CF, et al (1993). Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 196: 612-618.
23. Li CJ, Zhang LJ, et al (1993). Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci USA 90: 1839-1842.
24. Major EO, Amemiya K, et al (1992). Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 5: 49-73.
25. Moore RD, Chaisson RE (1999). Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13: 1933-1942.
26. Nicoli F, Chave B, et al (1992). Efficacy of cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 339: 306.
27. Portegies P, Algra PR, et al (1991). Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 337: 680-681.
28. Sacktor N, Lyles RH, et al (2001). HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56: 257-260.
29. Sausville EA, Horwitz SB (1978). Inhibition of SV40 DNA synthesis by camptothecin and neocarzinostatin. Mol Pharmacol 14: 1156-1166.
30. Tantisiriwat W, Tebas P, et al (1999). Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 28: 1152-1154.
31. Taoufik Y, Delfraissy JF, et al (2000). Highly active antiretroviral therapy does not improve survival of patients with high JC virus load in the cerebrospinal fluid at progressive multifocal leukoencephalopathy diagnosis. AIDS 14: 758-759.
32. Weiner SM, Laubenberger J, et al (2000). Fatal course of HIV-associated progressive multifocal leukoencephalopathy despite successful highly active antiretroviral therapy. J Infect 40: 100-102.
33. Yang L, Wold MS, et al (1987). Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc Natl Acad Sci USA 84: 950-954.
34. Yiannoutsos CT, De Luca A (2001). Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy. J Neuro Virol 7: 369-374.
35. Zhang JL, Sharma PL, et al (1997). Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I. Antimicrob Agents Chemother 41: 977-981.